Risk of pneumonia in patients with COPD initiating fixed dose inhaled corticosteroid (ICS) / long-acting bronchodilator (LABD) formulations containing extrafine beclometasone dipropionate versus patients initiating LABD without ICS

David Price* (Corresponding Author), William Henley, José Eduardo Delfini Cançado, Leonardo M Fabbri, Huib AM Kerstjens, Alberto Papi, Nicolas Roche, Elif Şen, Dave Singh, Claus F Vogelmeier, Elena Nudo, Victoria Carter, Derek Skinner, Rebecca Vella, Joan B Soriano, Maxim Kots, George Georges

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Risk of pneumonia in patients with COPD initiating fixed dose inhaled corticosteroid (ICS) / long-acting bronchodilator (LABD) formulations containing extrafine beclometasone dipropionate versus patients initiating LABD without ICS'. Together they form a unique fingerprint.

Medicine & Life Sciences